Mozobil for Autologous Hematopoietic Stem Cell Transplantation

This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been associated with a potentially higher incidence of engraftment syndrome. The trial aims to evaluate whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome.

NCT Number	NCT07188090
Lead Sponsor	Thomas Jefferson University
Conditions	Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma
Enrollment	100 participants
Start Date	2025-10-16
Primary Completion	2027-12 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2025-11-28